replique montre fausse rolex african american wigs diamond art Coronavirus Vaccine Market Demand Analysis 2020

Coronavirus Vaccine Market Demand Analysis 2020

By James Blunt 09 Apr 2020 Top stories,Health

The rapid increase of coronavirus all around the world is the driving factor for the global coronavirus vaccine market

The family of viruses that cause respiratory-related diseases in mammals and birds. Coronavirus cause respiratory tract infections in humans that can only cause common cold and others that cause severe respiratory problem and ultimately death such as SARS, MERS and recent COVID-19. Some of the identified corona viruses are SARS-CoV, HCoV NL63, HKU1, MERS-CoV and recent SARS-CoV-2.

The recent 2019-nCoV which was originated in Wuhan region of China is highly contagious in nature and affects the lungs severely where patient find it hard to breath. From decemebr 2019 to till date of march 26, 2020 there have been 472,529 confirmed cases and at least 21,305 deaths worldwide. This strain has been identified as a new strain of Betacoronavirus from group 2B with about 70% genetic similarity with SARS-CoV. It is declared as pandemic worldwide by WHO recently. Due to its highly contagious nature, about 35 companies and academic institutions are working hard to create a vaccine, at least four of which are having some sort of result they have been testing in animals. The vaccine produced by Boston based biotech firm Moderna is entering human trial shortly. This unparalleled speed is due to early Chinese efforts to sequence the Sars-CoV-2’s genetic materials that caused Covid-19. 

In case of severe acute respiratory syndrome (Sars) in China in 2002-04, and Middle East respiratory syndrome (Mers), which started in Saudi Arabia in 2012, work started on vaccine and later put on the side as the outbreaks were contained. Maryland-based Novavax, have now restated those vaccines for Sars-CoV-2.


I-Mab Biopharma has developed TJM2, a neutralizing antibody, as a treatment for cytokine storm in patients suffering from a severe case of coronavirus infection. The drug aims the human granulocyte-macrophage colony-stimulating factor (GM-CSF), which is responsible for severe and chronic inflammation.

Medicago is developing drug candidates against COVID-19 after producing Virus-Like Particles (VLP) of the coronavirus. The company has signed a collaboration with Laval University’s Infectious Disease Research Centre to develop antibodies against SARS-CoV-2. The company’s research activities are being partially funded by the Canadian Institutes for Health Research (CIHR).

Airway Therapeutics is researching its novel human recombinant protein named AT-100 (rhSP-D) as a possible treatment for coronavirus. The company has announced a filing with the Respiratory Diseases Branch of the National Institutes of Health to evaluate the drug.

Tiziana Life Sciences is developing a monoclonal antibody named TZLS-501 for the treatment of COVID-19. TZLS-501 is a human anti-interleukin-6 receptor (IL-6R), which helps in stopping lung damage and prominent levels of IL-6. The drug functions by binding to IL-6R and reducing the amount of IL-6 circulating in the body thereby decreasing chronic lung inflammation.

Inovio Pharmaceuticals has collaborated with Beijing Advaccine Biotechnology organization to advance the development of the former’s vaccine, INO-4800, as a novel coronavirus vaccine. The company has begun pre-clinical testing for clinical product manufacturing.

in partnership with GeneOne Life Science, Inovio has developed the investigational DNA immunotherapy, INO-4700 (GLS-5300) as the MERS CoV Vaccine. It is delivered as vaccine intramuscularly, using the Cellectra® delivery device. The company has received a USD 5m grant from the Bill and Mellinda Gates foundation to quicken the development of the Cellectra® delivery device.

The North America is estimated to have high growth rate and revenue share in global coronavirus vaccine market due to presence major companies and research organizations who are conducting research such as Novavax, moderna etc. and growing number of cases in USA. Europe is estimated to be the second highest market due to serious health condition occurred due to corona virus pandemic and urgent need of vaccines in this region. In case of Asia-pacific the market is estimated to have highest growth rate due to it being as the origin place of corona virus, extensive research in China, rising demand as well as presence of dense human population.

Get Fill Report @

Interested in this report?

Get Your Sample Now!

James Blunt

One of the youngest and hardworking members of the team, James Blunt is known for attaining career heights in a short span of time. He has been a part of the Business Stats News for 4 years now and takes care of the Health domain of the website single-handedly. James is given the responsibility to write articles and blogs relating to health such as new discoveries, clinical trials, disease outbreaks.

Related Post

    No Record Found